Literature DB >> 3965507

Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity.

D Stern, P Nawroth, J Marcum, D Handley, W Kisiel, R Rosenberg, K Stern.   

Abstract

Bovine antithrombin III (AT III) interaction with the luminal surface of bovine aortic segments with a continuous layer of endothelium was examined. Incubation of 125I-AT III with vessel segments, previously washed free of endogenous AT III, demonstrated specific, time-dependent binding to the protease inhibitor to the endothelium. Half-maximal binding was observed at an added AT III concentration of 14 nM. Binding of 125I-AT III to the vessel wall was reversible (50% dissociated in 4 min), and addition of either heparin or Factor Xa accelerated displacement of 125I-AT III from the vessel segment. Dissociation of 125I-AT III from the vessel segment in the presence of factor Xa coincided with the formation of a Factor Xa-125I-AT III complex. Inactivation of Factor IXa and Factor Xa by AT III was facilitated in the presence of vessel segments. Pretreatment of vessel segments with highly purified Flavobacterium heparinase precluded the vessel-dependent augmentation of AT III anticoagulant activity as well as specific binding of 125I-AT III to the vessel endothelium. In contrast, pretreatment of the vessel segments with chrondroitinases (ABC or AC) had no detectable effect on 125I-AT III binding or on AT III anticoagulant activity. AT III binding to vessel segments was competitively inhibited by increasing concentration of platelet factor 4. Binding of the protease inhibitor to vessel segments was inhibited by chemical modification of AT III lysyl or tryptophan residues. These AT III derivatives retained progressive inhibitory activity. These data suggest that heparin-like molecules are present on the aortic vessel wall and mediate binding of AT III to the vessel surface, as well as enhancing the anticoagulant activity of AT III at these sites.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965507      PMCID: PMC423436          DOI: 10.1172/JCI111685

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Anticoagulant action of heparin.

Authors:  P S Damus; M Hicks; R D Rosenberg
Journal:  Nature       Date:  1973-12-07       Impact factor: 49.962

2.  Comparison of the esterase activities of trypsin, plasmin, and thrombin on guanidinobenzoate esters. Titration of the enzymes.

Authors:  T Chase; E Shaw
Journal:  Biochemistry       Date:  1969-05       Impact factor: 3.162

3.  The purification and mechanism of action of human antithrombin-heparin cofactor.

Authors:  R D Rosenberg; P S Damus
Journal:  J Biol Chem       Date:  1973-09-25       Impact factor: 5.157

4.  Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X.

Authors:  S P Bajaj; K G Mann
Journal:  J Biol Chem       Date:  1973-11-25       Impact factor: 5.157

5.  Transformation of active-site lysine in naturally occurring trypsin inhibitors. A basis for a general mechanism for inhibition of proteolytic enzymes.

Authors:  R Haynes; R E Feeney
Journal:  Biochemistry       Date:  1968-08       Impact factor: 3.162

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Biological properties of the naturally occurring plasma inhibitor to activated factor X.

Authors:  E T Yin; S Wessler; P J Stoll
Journal:  J Biol Chem       Date:  1971-06-10       Impact factor: 5.157

8.  Radioimmunoassay of platelet factor 4.

Authors:  K L Kaplan; J Owen
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

9.  Bovine factors X 1 and X 2 (Stuart factor). Isolation and characterization.

Authors:  K Fujikawa; M E Legaz; E W Davie
Journal:  Biochemistry       Date:  1972-12-19       Impact factor: 3.162

10.  Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia.

Authors:  K A Bauer; J B Ashenhurst; J Chediak; R D Rosenberg
Journal:  Blood       Date:  1983-12       Impact factor: 22.113

View more
  17 in total

1.  Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.

Authors:  K A Bauer; L M Weiss; D Sparrow; P S Vokonas; R D Rosenberg
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

2.  Interaction of vitamin-K-dependent coagulation factors and the endothelium.

Authors:  P P Nawroth; D M Stern
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

3.  Thrombo-embolic complications after splenectomy in HbE-beta-thalassaemia.

Authors:  F A Wijburg; W van den Berg; A van Teunenbroek; R S Weening
Journal:  Eur J Pediatr       Date:  1988-05       Impact factor: 3.183

4.  An endothelial cell-dependent pathway of coagulation.

Authors:  D Stern; P Nawroth; D Handley; W Kisiel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

Review 5.  The haemostatic function of the vascular endothelial cell.

Authors:  H A Bull; S J Machin
Journal:  Blut       Date:  1987-08

Review 6.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

Review 7.  Clearance of thrombin in vivo: significance of alternative pathways.

Authors:  T H Carlson
Journal:  Mol Cell Biochem       Date:  1986-08       Impact factor: 3.396

8.  PF4/heparin complexes are T cell-dependent antigens.

Authors:  Shayela Suvarna; Lubica Rauova; Emily K E McCracken; Christina M Goss; Bruce S Sachais; Steven E McKenzie; Michael P Reilly; Michael Dee Gunn; Douglas B Cines; Mortimer Poncz; Gowthami Arepally
Journal:  Blood       Date:  2005-04-21       Impact factor: 22.113

9.  Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia.

Authors:  Bruce S Sachais; Ann H Rux; Douglas B Cines; Serge V Yarovoi; Lee I Garner; Stephen P Watson; Jillian L Hinds; John J Rux
Journal:  Blood       Date:  2012-03-27       Impact factor: 22.113

10.  Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency.

Authors:  K A Bauer; T L Goodman; B L Kass; R D Rosenberg
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.